Lv6
2060 积分 2024-03-18 加入
Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target
14天前
已完结
Safety, tolerability, and pharmacokinetics of HL-300, a novel topical pan-JAK inhibitor, in healthy Chinese adults: a first-in-human, randomized, double-blind, placebo-controlled phase I trial
17天前
已完结
Systemic Pharmacokinetics, Safety, and Preliminary Efficacy of Topical AhR Agonist Tapinarof: Results of a Phase 1 Study
18天前
已完结
[Chinese expert consensus on the key diagnostic points of uveitis (2025)]
27天前
已完结
Efficacy and Safety of SJP-0132 in Patients With Dry Eye Disease: A Phase 2b Randomized, Double-Masked, Dose-Finding Study
1个月前
已完结
Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC)
1个月前
已完结
A randomized, double-blind, placebo-controlled phase 1 trial of the topical pan–lysyl oxidase inhibitor PXS-6302 in mature scars
2个月前
已完结
A Clinimetric Overview of Scar Assessment Scales
2个月前
已完结
Rating the resolving hypertrophic scar: Comparison of the Vancouver Scar Scale and scar volume
2个月前
已关闭
Determination of Inter-Rater Reliability in Pediatric Burn Scar Assessment Using a Modified Version of the Vancouver Scar Scale
2个月前
已完结
皖公网安备34019202002308
